Currently, there are 119.84M common shares owned by the public and among those 104.37M shares have been available to trade.
The company’s stock has a 5-day price change of 13.17% and -11.28% over the past three months. HUMA shares are trading 63.38% year to date (YTD), with the 12-month market performance up to 69.34% higher. It has a 12-month low price of $2.48 and touched a high of $9.97 over the same period. HUMA has an average intraday trading volume of 3.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.83%, -4.39%, and -14.52% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Humacyte Inc (NASDAQ: HUMA) shares accounts for 27.90% of the company’s 119.84M shares outstanding.
It has a market capitalization of $800.63M and a beta (3y monthly) value of 1.45. The earnings-per-share (ttm) stands at -$1.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.33% over the week and 10.31% over the month.
Earnings per share for the fiscal year are expected to decrease by -26.44%, and 36.22% over the next financial year.
Looking at the support for the HUMA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 20, 2024, with the firm’s price target at $12-$15. H.C. Wainwright coverage for the Humacyte Inc (HUMA) stock in a research note released on December 11, 2023 offered a Buy rating with a price target of $6. Piper Sandler was of a view on August 14, 2023 that the stock is Neutral, while Cantor Fitzgerald gave the stock Overweight rating on June 22, 2023, issuing a price target of $6. Piper Sandler on their part issued Underweight rating on May 16, 2022.
